Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure

Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial

Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax^TM COVID-19 Vaccine in Japan to Moderna

Takeda Announces Approval of Nuvaxovid^® COVID-19 Vaccine for Primary and Booster Immunization in Japan

Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan